Strategic Partnerships Theolytics is actively establishing select strategic partnerships to expand and accelerate pipeline development across solid and liquid tumors, offering collaboration models such as co-development, licensing, or joint funding to leverage their intravenous ready oncolytic platform and lead programs.

Ovarian Cancer Focus Lead candidate THEO-260 targets ovarian cancer with intraperitoneal delivery in platinum-resistant cases; an ongoing Phase 1 OCTOPOD-IP trial is being presented as a trial in progress at ASCO 2026, signaling near-term data opportunities for partners to evaluate licensing or co-development.

Public Funding Advantage Recent non-dilutive Horizon Europe funding and Innovate UK Transforming Cancer Therapeutics grants demonstrate a favorable financing backdrop that can de-risk deals, enable joint grant applications, and accelerate early-stage collaboration timelines.

Leadership Momentum Recent leadership appointments and high-profile conference appearances indicate strengthened governance and credible clinical development leadership, which can shorten partner negotiations and bolster confidence in joint development plans.

Outsourcing Opportunity With a small team and a pipeline requiring specialized development, Theolytics is well positioned to engage CROs and CDMOs for oncolytic therapy programs, allowing partners to access leading-edge science without large internal investments.